NEW YORK – Johns Hopkins University spinout Delfi Diagnostics has staked its claim in the growing push to harness genomic and epigenomic technologies for non-invasive early cancer detection and screening.
Announcing a $100 million financing on Tuesday, the company emerged from what has been a quiet period since its founding in 2019, disclosing plans to use the funding to support clinical validation of its technology through prospective studies.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
